<div id="readability-page-1">04:16 AM EST, 12/15/2025 (MT Newswires) -- Johnson &amp; Johnson ( JNJ ) said late Friday that the US Food and Drug Administration has approved the supplemental new drug application for Akeega plus prednisone for the treatment of patients with a certain indication of metastatic castration-sensitive prostate cancer.The approval was based on positive results from a phase 3 clinical study in which the drug combination significantly reduced the risk of radiographic progression or death by 54% compared with a placebo, the company said. It also prolonged the time to symptomatic progression by 59%, the company said.The safety profile of the combination was consistent with other FDA-approved therapies, the company said.Prostate cancer patients with the indication, called a BRCA mutation, often have more aggressive forms of the disease, the company said. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

Johnson & Johnson announced FDA approval for its prostate cancer therapy, Akeega plus prednisone, targeting metastatic castration-sensitive prostate cancer with BRCA mutation. The approval follows a phase 3 study showing a 54% reduction in radiographic progression or death risk and a 59% delay in symptomatic progression. The safety profile aligns with other FDA-approved therapies.

Johnson & Johnson's Prostate Cancer Therapy Application Approved by US FDA